Pharmaceutical company · ABBV

AbbVie
clinical trial
pipeline

Registry checked

Published

Upadacitinib is linked to 20 distinct active studies, with 2 Phase 1, 17 Phase 3, 1 without a recorded phase. Telisotuzumab Adizutecan is linked to 16 distinct active studies, with 3 Phase 1, 9 Phase 2, 4 Phase 3.

34 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

242active trials
as lead sponsor
  • Phase 151
  • Phase 262
  • Phase 373
  • Phase 45
  • Phase not recorded51

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

5029 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

NCT07856706 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
29 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-051300043
2026-10-060000000
2026-10-071010021
2026-10-080100122
2026-10-091000011
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-132110042
2026-10-141010021
2026-10-151120042
2026-10-163330093
2026-10-172100032
2026-10-180000000
2026-10-191110143
2026-10-200000000
2026-10-212100032
2026-10-220000000
2026-10-230000000
2026-10-240000221
2026-10-250000000
2026-10-260000000
2026-10-270001011
2026-10-280001011
2026-10-292110152
2026-10-301001022
2026-10-310000111
Type totals181310365029 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Upadacitinib

Rinvoq

20
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 317
  • Phase 40
  • Phase not recorded1
Studied condition
Alopecia Areata · Atopic Dermatitis · Axial Spondylarthritis (r-axSpA)
Next primary completion
Nov 2026 · estimated
Open drug

Telisotuzumab Adizutecan

Canonical investigational asset

16
Active trials
10
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 29
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumors · Biliary Tract Cancers · c-MET
Next primary completion
Dec 2026 · estimated
Open drug

Risankizumab

skyrizi

14
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 22
  • Phase 310
  • Phase 40
  • Phase not recorded1
Studied condition
Crohn's Disease · Crohn's Disease (CD) · Healthy Volunteer
Next primary completion
Mar 2027 · estimated
Open drug

Etentamig

Canonical investigational asset

12
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 15
  • Phase 23
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Amyloid Light Chain (AL) Amyloidosis · Immunoglobulin Light Chain (AL) Amyloidosis · Multiple Myeloma
Next primary completion
Not reported
Open drug

Venetoclax

venclexta

8
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 23
  • Phase 33
  • Phase 42
  • Phase not recorded0
Studied condition
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Acute Myeloid Leukemia (AML)
Next primary completion
Nov 2026 · estimated
Open drug

Lutikizumab

Canonical investigational asset

7
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 26
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Atopic Dermatitis · Hidradenitis Suppurativa · Psoriatic Arthritis
Next primary completion
Dec 2026 · estimated
Open drug

181 of 242 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 181 of 242 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

AbbVie trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Switch-Up
Upadacitinib

NCT06389136

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

6 candidate observations · 3 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • status flip · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • enrollment change · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 14 Jun 2024 · actual
Primary completion: Nov 2026 · estimated
Study completion: May 2027 · estimated

2021202220232024202520262027202820292030
ReVenG
Venetoclax

NCT04895436

Phase 2 · Recruiting

Trial source and qualifications

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 28 Mar 2022 · actual
    Primary completion: Nov 2026 · estimated
    Study completion: Jan 2029 · estimated

    2021202220232024202520262027202820292030
    Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
    Mirvetuximab Soravtansine

    NCT05456685

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 28 Sept 2022 · actual
      Primary completion: Nov 2026 · estimated
      Study completion: Nov 2026 · estimated

      2021202220232024202520262027202820292030
      LIVIGNO-1
      Budigalimab

      NCT05822752

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

      0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      No eligible observations recorded in the inspected period.

        Start: 21 Sept 2023 · actual
        Primary completion: Nov 2026 · estimated
        Study completion: Nov 2026 · estimated

        2021202220232024202520262027202820292030
        Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
        ABBV-932

        NCT06846320

        Phase 2 · Recruiting

        Trial source and qualifications

        Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 29 Apr 2025 · actual
          Primary completion: Nov 2026 · estimated
          Study completion: Nov 2026 · estimated

          2021202220232024202520262027202820292030
          ATMOSPHERE
          Surabgene Lomparvovec

          NCT04704921

          Phase 3 · Active, not recruiting

          Trial source and qualifications

          Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

          Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

          Start clipped at the display horizon.

          6 candidate observations · 0 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          6 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 29 Dec 2020 · actual
            Primary completion: Dec 2026 · estimated
            Study completion: Nov 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 95 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 9 actual primary completions, 0 untyped primary completions, 8 past estimates, 23 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            90

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology90 trials
            • Immunology & Inflammation38 trials
            • Dermatology24 trials
            • Neurology14 trials
            • Ophthalmology10 trials
            • Psychiatry & Addiction7 trials
            • Metabolic/Endocrine/Nutrition3 trials
            • Haematology2 trials
            • Pain & Musculoskeletal2 trials
            • Anaesthesia & Perioperative Care1 trials
            • Cardiovascular1 trials
            • Gastroenterology & Hepatology1 trials
            • Respiratory1 trials
            • Womens Health1 trials
            • Unmapped34 trials
            • Healthy volunteers13 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            R

            Roche

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 2,320 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: AbbVie. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            2,333 distinct registry candidates produced 2,320 accepted studies. 0 mapped to other owners, 13 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 188 unverified, 0 identity-only and 50 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            1,947 scoped records have indexed enrichment and 373 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T00:10:59.661Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 1a4dcf35d3f69a38668b79dd4b93dee061e45498dc845418e814c707a0ce03e3.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 2,320 mapped lead-sponsored clinical studies across all statuses. 1,947 have indexed enrichment, 373 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.